Literature DB >> 25873560

Prognostic Value of C-met Expression in Cholangiocarcinoma.

Zhi-Yuan Mao1, Guang-Qing Zhu2, Li Ren3, Xiao-Chuan Guo4, Dan Su4, Li Bai4.   

Abstract

AIM: To explore the relationship of clinicopathological features and the proteins of C-met expression in the prognosis of cholangiocarcinoma.
METHODS: Clinical data and the completed follow-up information of patients with cholangiocarcinoma who underwent cholangiocarcinoma operation from January 2004 to December 2010 were analyzed retrospectively. The relationship of clinicopathological features and C-met in the prognosis of the patients was analyzed.
RESULTS: Patients with high expression of C-met had significantly shorter overall survival than those with low expression of C-met, the difference being statistically significant (P = .003). Patients with high C-met expression had significantly shorter disease-free survival time than those with low expression of C-met, the difference being statistically significant (P = .009). By COX multivariate analysis, high C-met expression in tumor tissues was an independent risk factor in predicting overall survival and disease-free survival for patients with cholangiocarcinoma (P = .038, .048, relative risk = 1.390, 1.427).
CONCLUSION: Patients with high C-met expression in cancer tissues had shorter disease-free survival and overall survival. High expression of C-met is an independent risk factor for overall survival and disease-free survival.
© The Author(s) 2015.

Entities:  

Keywords:  C-met; cholangiocarcinoma; prognosis; surgery; tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 25873560     DOI: 10.1177/1533034615578959

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  2 in total

1.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.

Authors:  Kai Wei; Mao Li; Margot Zöller; Meng Wang; Arianeb Mehrabi; Katrin Hoffmann
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

Review 2.  Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature.

Authors:  Daniel S Lefler; Marni Brisson Tierno; Babar Bashir
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.